Answers are grounded in this paper and cite their sources.
Lay Summary The JAK/STAT inhibitor tofacitinib, recently approved for the treatment of ulcerative colitis, is found to modulate the intestinal endothelial barrier functions in directing the leukocyte adhesion and transmigration in ulcerative colitis patients displaying high levels of endothelial STAT3/STAT6 phosphorylation.
No takes yet. Share an insight, caveat, or question.
Massimino et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: